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Abstract
Background Exchangeable neck stems, defined as those
with a dual taper (that is, a modular junction between the
femoral head and the femoral neck and an additional
junction between the neck and the stem body), were
introduced in THA to improve restoration of joint
biomechanics (restoring anteversion, offset, and limb
length) and reduce the risk of dislocation. However
exchangeable necks have been reported to result in
adverse effects such as stem fractures and acute local
tissue reaction. Whether they result in a net improvement
to or impairment of reconstructive survivorship remains
controversial.
Questions/Purposes (1) To compare the prosthetic sur-
vivorship and all-cause revision risk of exchangeable
femoral neck THAs versus fixed neck THAs, taking known
prosthetic revision risk factors into account; and (2) to
compare the cause-specific revision risk of exchangeable
femoral neck THAs versus fixed neck THAs, adjusting for
known prosthetic risk factors.
Methods Using French national health-insurance
databases, we identified all French patients older than
40 years who underwent primary THA from 2009
through 2012. To ensure accuracy of the data, we con-
sidered only beneficiaries of the general insurance
scheme (approximately 77% of the population). Char-
acteristics of the prosthesis and the patients receiving an
exchangeable femoral neck THA were compared with
those receiving a fixed femoral neck THA (defined as
femoral stem with only the head being exchangeable).
Revision was the event of interest. Followup started on
the date the THA was performed, until the patient
experienced revision, died, was lost to followup, or
until the followup period ended (December 31, 2014),
whichever came first. Competing risk THA survivorship
was calculated and compared (purpose 1), as were
cause-specific Cox regression models (purpose 2). The
study cohort included 324,108 individuals with a mean
age of 77 years. A total of 24% underwent THA for
acute trauma, and 3% of the group received an
exchangeable neck THA. During the median 45-month
followup (mean, 42 months; minimum, 1 day;
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maximum, 6 years), 11,968 individuals underwent
prosthetic revision.
Results The cumulative revision incidence was 6.5%
(95% CI, 5.8%–7.3%) for exchangeable neck THAs versus
4.7% (95% CI, 4.6%–4.8%) for fixed neck THAs (p \
0.001). After controlling for potential confounding vari-
ables including age, sex, comorbidities, indication for
THA, cementation, bearing surface, and the characteristics
of the center where the implantation was performed, we
found that the exchangeable femoral neck THA was
associated with an increased hazard ratio (HR) of revision
of 1.26 (95% CI, 1.14–1.38; p\0.001) compared with the
fixed neck THA. When dealing with cause-specific revi-
sion, exchangeable neck THAs had a higher incidence of
revision for implant failure or periprosthetic fracture, and
for mechanical complications; adjusted HRs were,
respectively, 1.68 (95% CI, 1.24–2.27; p\0.001) and 1.27
(95% CI, 1.13–1.43; p\ 0.001), for exchangeable neck
THAs compared with fixed ones.
Conclusions Exchangeable neck THAs had poorer sur-
vivorship independent of other prosthetic revision risk
factors. Accordingly, expected anatomic and functional
benefits should be carefully assessed before choosing this
design.
Level of Evidence Level III, therapeutic study.
Introduction
Adjusting limb length, femoral offset, and implant
positioning are all important to achieve a successful
outcome of THA. Available techniques and technical
options in the field of hip arthroplasty have been
evolving for several decades; in the 1980s, exchange-
ability of the femoral neck was introduced to help
surgeons in customizing the THA fit and matching the
anatomic characteristics of the patient with better accu-
racy to improve ROM, stability, and abductor strength
[23, 26, 42, 44]. Exchangeable neck stems—defined as
those with modular junctions between the femoral head
and the femoral neck and between the neck and the stem
body—allow the surgeon to adjust limb length, femoral
offset, and femoral anteversion independently from stem
size or position.
Exchangeable necks are considered particularly useful
to accommodate difficult cases of femoral deformity
[35, 57], to restore joint biomechanics, and prevent pros-
thetic impingement-related complications. However, they
also have been reported to result in adverse effects,
including fretting, corrosion, implant failure, metallic wear
debris generation [10, 19, 27, 30, 46], and local tissue
reaction [10, 24, 29, 51]. Whether they result in a net
improvement to or impairment of reconstructive
survivorship remains controversial [8, 13, 14, 34, 50, 52].
Few studies have compared prosthetic survivorship of
exchangeable neck versus fixed neck THAs, and findings
are divergent [2, 14, 17]. The Australian Orthopaedic
Association National Joint Replacement Registry reported
exchangeable neck stem THAs have a higher rate of
revision (almost twice) at 10 years compared with fixed
neck stem THAs, in patients with osteoarthritis, regard-
less of the bearing surface [2]; Meftah et al. [33] also
found a high cumulative revision rate with one specific
model of exchangeable neck THA, but did not have a
comparison group with fixed neck THA. Others found no
difference [17, 18, 43, 50]. Except for the Australian
registry from a population-based cohort (albeit one in
which data on patients’ medical histories are limited), all
other studies on this topic have been performed on small
cohorts and often without a comparative group of fixed
neck THAs. In addition, to our knowledge, none investi-
gated prosthetic survivorship of exchangeable neck versus
fixed neck THAs according to the implantation indication
osteoarthritis (meaning degenerative or posttraumatic
arthritis) or traumatic indication, and none explored cau-
ses for revision.
We therefore sought (1) to compare the prosthetic sur-
vivorship and all-cause revision risk of exchangeable
femoral neck THAs versus fixed neck THAs, taking known
prosthetic revision risk factors into account; and (2) to
compare the cause-specific revision risk of exchangeable
femoral neck THAs versus fixed neck THAs, adjusting for
known prosthetic risk factors.
Patients and Methods
We retrospectively used the French Health Insurance
Information System (SNIIRAM), which has been validated
[3, 20–22, 31, 37] and used in many studies
[4–6, 9, 15, 28, 31, 32, 48, 49, 58, 59]. In France, health
insurance is compulsory and it comprehensively covers the
entire French population. It is divided into three main
schemes: (1) general scheme covering employees in the
industry, business, and service sectors, and some categories
of workers considered as employees; (2) agricultural
scheme covering farmers and farm employees; and (3)
social scheme for independent professionals covering
craftspeople, retailers, manufacturers, and independent
workers. In our study, only the general scheme beneficia-
ries were included (approximately 77% of the population),
because of technical reasons: for beneficiaries of other
schemes, some information regarding medical details,
long-term disease, or date of death do not follow the same
recording process in the databases and are available only
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partially or with long delays. For beneficiaries of the
general scheme, the SNIIRAM records with dates, outpa-
tient drugs (Anatomical Therapeutic Classification codes),
medical devices, services, and procedures reimbursed. The
database does not specifically link indications for use of a
particular device, service, or procedure to a reimbursement
code, but contains patients’ demographic, administrative,
and medical details (chronic conditions such as diabetes
mellitus, cancer, or cardiovascular disease), and date of
death. An anonymous, unique patient identifier links
SNIIRAM information to national hospital discharge
databases (Programme de Me´dicalisation des Syste`mes
d’Information [PMSI]), providing reasons for admission
and discharge diagnoses (using International Statistical
Classification of Diseases, 10th Revision [ICD-10]).
A population-based cohort of patients having primary
THA was identified by the hospitals’ procedure claims and
medical devices reimbursed; this method has been used and
validated [20, 21]. The eligible population was all patients
40 years or older, having undergone unilateral primary
THA between January 1, 2009, and December 31, 2012 (48
months). Patients having received primary THA for bone
cancer, prosthetic revision before the index date, simulta-
neous bilateral THA, not having received any
reimbursement 6 months after THA (therefore impossible
to followup: n = 767; 0.2%), or with incoherent data in the
PMSI were excluded (n = 19,564; 3.8%). THA character-
istics were missing for 5639 (1.7%), who were excluded
from subsequent analyses, leaving 324,108 (Fig. 1), among
which 246,940 received implants for osteoarthritis and
77,168 received implants owing to acute trauma; 79,605
were enrolled in 2009, 80,226 in 2010, 81,654 in 2011, and
82,623 in 2012. Twenty five thousand four hundred sev-
enty-three patients (7.9%) were lost to followup (their
mean followup was 908 days, versus 1436 days for patients
followed up to December 31, 2014).
Approval was obtained from the French data protection
agency (Commission Nationale de l’Informatique et des
Liberte´s). Informed consent was not required because
information was collected anonymously.
Two types of necks were considered: an exchangeable
femoral neck and a fixed femoral neck. Exchangeable
femoral necks were defined as a femoral stem with a dual
taper, meaning a trunnion between the femoral head and
neck, and an additional trunnion between the neck and
body of the stem. Fixed femoral neck implants were
defined as femoral stems with only the femoral head being
exchangeable (that is, the stem body and neck are mono-
lithic, but the head is modular) (Fig. 2).
The primary outcome was THA revision (including any
surgical revision in which the implant or any component
was changed or removed), regardless of the cause for that
revision. We also identified causes for revision with algo-
rithms based on the reason for admission, procedures coded
in hospital claims, and medications reimbursed. We clas-
sified them as revision ‘‘for implant failure or
periprosthetic fracture,’’ ‘‘for dislocation,’’ ‘‘for infection,’’
or ‘‘for mechanical complication’’ (including aseptic loos-
ening, osteolysis, corrosion, adverse tissue reactions).
When it was not possible to identify the cause for revision,
we stated ‘‘unspecified cause.’’ Followup started at the date
the THA was performed (index date) until the patient
underwent revision surgery, was lost to followup (not
receiving any medical care reimbursements recorded in the
databases), died, or until the followup ended (December
31, 2014), whichever came first. Median followup was 45
months (mean, 42 months; minimum, 1 day; maximum, 6
years). Patient death was considered a competing risk.
We collected a series of patient, implantation center, and
THA characteristics known to be or suspected of being
associated with a risk of postarthroplasty complications.
Information regarding patients’ age, sex, and date of death
came from the SNIIRAM database. Treatments were
identified by prescriptions (Anatomical Therapeutic Clas-
sification codes) reimbursed at least once within 180 days
before or after inclusion, namely antidepressants, antihy-
pertensives, oral corticosteroids, osteoporosis treatments,
psychostimulants, antiepileptics, benzodiazepines, anxi-
olytic or hypnotic nonbenzodiazepines (non-BZD), and
antipsychotics. Diabetes mellitus, morbid obesity (corre-
sponding to a BMI greater than 30 kg/m2), Parkinson’s
disease, immunodeficiency, and chronic kidney disease
were defined (ICD-10 categories) on the basis of hospital
discharge reports or chronic condition recorded the year
before inclusion, with relevant prescriptions. The indica-
tion for THA (osteoarthritis or traumatic indication) was
identified based on hospital discharge reports. The mean
number of THAs performed per month (during the 4-year
inclusion period) was calculated. Whether centers where
the THAs were performed were private or public and the
duration of hospital stay (in days) also were collected. Four
types of THA fixation techniques (uncemented, both sides
cemented, hybrid [femoral component cemented, acetabu-
lar component uncemented], and reverse hybrid [femoral
component uncemented, acetabular component cemen-
ted]), and four different bearings (ceramic-on-ceramic
[CoC], ceramic-on-polyethylene [CoP], metal-on-metal
[MoM], and metal-on-polyethylene [MoP]) were analyzed.
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Statistical Analysis
Cumulative incidence of revision (whatever the cause) was
represented according to type of femoral neck using a Fine
and Gray [16] proportional hazards regression model with
death as a competing risk. Hazard ratios (HRs) for revision
according to the type of femoral neck were assessed using
univariate and multivariate Fine and Gray proportional
hazards regression models adjusting for possible con-
founding factors: sex; age category at implantation: young
(40–59 years), middle-aged (60–74 years), or elderly (C 75
years); indication for implantation (osteoarthritis, trau-
matic); diabetes mellitus; morbid obesity; Parkinson’s
disease; immunodeficiency; medication (antidepressants,
oral corticosteroids, antiosteoporotics, psychostimulants,
benzodiazepines, non-BZD antiepileptics, non-BZD anxi-
olytic/hypnotic, antipsychotics); public or private sector;
center activity volume (tertiles); hospital stay duration
(three groups:\ 6 days; 6–12 days;[ 12 days); cement
type (four categories); and bearing surface (four
526,865 Inial Populaon
27,354  Excluded
5593  Died During The Hospital Stay For The 
Implant Procedure
2197  Simultaneous Bilateral 
Implant (Performed During The Same
Hospital Stay)




61,683  Revision 2006-Baseline (PMSI)
106,952  Other Scheme Than General One 
767  Did Not Receive Any Health 
Insurance Reimbursement
Aer The Hospital   
Stay For The THA
362  THA Because Of Bone Tumor
329,747  Populaon Enrolled
5639  Unspeciﬁed Prosthec Characteriscs
324,108  Populaon Analysed
246,940 for Degenerave or Posttraumac 
Arthris Indicaon
77,168 for Traumac Indicaon
Fig. 1 A flow chart of our
study population is shown.
PMSI = Programme de Me´di-
calisation des Syste`mes
d’Information.
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categories). These characteristics were included simulta-
neously in the multivariate Fine and Gray proportional
hazards regression model [16].
We also fitted cause-specific Cox proportional hazards
regression models for the following five indications for
revision: implant failure or periprosthetic fracture, dislo-
cation, infection, mechanical complication, and other
cause, and we estimated cause-specific adjusted HRs.
Assumption of proportional hazards was graphically as-
sessed for each variable. Interactions between exposure and
age and sex, indication, cement type, and bearing surface in
association with prosthetic survivorship were investigated,
and we performed analyses stratified on sex, age group,
indication, cementation type, and bearing surface.
Cohort Description at Inclusion
The median age of the 324,108 patients included was 74
years (interquartile range, 64–81 years; mean, 72.6 years;
SD, 11.7 years). Twenty-four percent of patients underwent
THA for a traumatic indication. Sixty-two percent of the
enrolled patients were women, and more likely received
THA for a traumatic indication (29% versus 15% for men, p
\0.001), and were older than the men (75 versus 69 years,
p\0.001) (Supplemental Table 1. Supplemental materials
are available with the online version of CORR1.).
Implantation was performed at a private-sector hospital in
58% of patients and 71% of procedures were performed in
centers in which more than 14 procedures per month were
done. Fixation was uncemented in 71% of patients,
cemented in 11%, hybrid in 17%, and reverse hybrid in 2%.
Bearing surfaces were CoC (32%), CoP (17%), MoM (3%),
and MoP (48%). We also reported characteristics at
inclusion, according to sex and indication for THA (Sup-
plemental Table 1. Supplemental materials are available
with the online version of CORR1.).
An exchangeable femoral neck was implanted in a total
of 8931 (3%) patients, with a stable proportion with time:
2.7% of patients included in 2009, 2.9% in 2010, 2.7% in
2011, and 2.8% in 2012. We reported patient characteris-
tics, hospital stay, and bearing surface at inclusion,
according to the type of femoral neck (Table 1).
Exchangeable neck THAs are performed more frequently
in young patients and in patients not experiencing trauma,
and are performed mostly in public hospitals. Implants with
neck exchangeability also are associated with other THA
characteristics: they are used more frequently with MoM
and CoC bearing surfaces and with uncemented THAs.
Type of femoral neck was strongly associated with the
hospital where the THA was performed. Among 891 cen-
ters where implants were performed, more than 5% of
exchangeable neck THAs were done in 100 centers
(globally, 21% of exchangeable neck THAs were per-
formed at these 100 centers versus 0.47% among the 791
others; p\0.0001). These 100 centers were more likely to
be public hospitals (nine were teaching hospitals) with
more than 38 procedures being performed per month. The
characteristics of patients receiving THAs at centers per-
forming low numbers of exchangeable neck implants
versus at centers performing high numbers of exchangeable
neck implants were similar.
Results
Survivorship and All-cause Revision
Patients receiving exchangeable neck stem implants were
more likely to undergo revision than those with fixed neck
stems designs (HR, 1.36; 95% CI, 1.24–1.49; p\ 0.001).
The cumulative incidence of prosthetic revision was 7% for
THAs with exchangeable neck implants versus 5% for
THAs with fixed neck implants (Fig. 3). After controlling
for potential confounding variables such as patient age,
sex, comorbidities, indication for THA, cementation,
bearing used, and the center characteristics, we found that
implantation of an exchangeable femoral neck design was
associated with an increased adjusted HR of revision of
1.26 (95% CI, 1.14–1.38; p\ 0.001) compared with fixed
neck design (Table 2). This association had the same pat-
tern for both implantation indications: adjusted HRs for
revision for exchangeable neck THAs were 1.25 (95% CI,
1.13–1.39) and 1.19 (95% CI, 0.94–1.51) compared with
fixed neck THAs in patients implanted for an indication of
osteoarthritis or a traumatic indication, respectively. Other
characteristics, including gender, age, indication for
Fig. 2A–B An (A) exchangeable femoral neck stem and (B) a fixed
femoral neck stem are shown. An exchangeable femoral neck stem
has a trunnion between the neck and ball head, and an additional
trunnion between the neck and body of the stem. A fixed femoral neck
stem has a trunnion only between the neck and ball head.
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Table 1. Baseline characteristics according to type of femoral neck
Fixed neck (%) Exchangeable neck (%) p Value*
Covariates Number (n = 315,177) (n = 8931)
THA characteristics
Cement type \ 0.001
Cemented 34,376 11 3
Hybrid 53,611 17 9
Reverse hybrid 5040 2 2
Uncemented 231,081 71 86
Bearing surface \ 0.001
CoC 104,584 32 46
CoP 56,055 17 14
MoM 8667 3 6
MoP 154,802 48 35
Patient characteristics
Sex \ 0.001
Male 122,178 38 42
Female 201,930 62 58
Age category (years) \ 0.001
40–59 46,945 14 21
60–74 122,590 38 43
C 75 154,573 48 37
Trauma indication 77,168 24 16 \ 0.001
Parkinson disease 13,158 4 3 \ 0.001
Diabetes mellitus 40,475 13 13 0.18
Morbid obesity 24,678 8 8 0.03
Treatments
Benzodiazepine 163,289 50 50 0.24
AH no BZD 45,534 14 14 0.37
Antidepressant 73,418 23 21 \ 0.001
Antipsychotic 22,364 7 6 \ 0.001
Psychostimulant 3386 1 1 0.62
Antiosteoporotic 42,311 13 12 0.02
Oral corticosteroı¨ds 83,198 26 27 0.02
Hospital characteristics
Sector \ 0.001
Public 136,853 41 71
Private 187,255 59 29
Number of THAs per month \ 0.001
\ 14 93,647 49 42
14–38 158,262 29 33
[ 38 72,199 22 25
Hospital stay duration (days) \ 0.001
\ 6 15,952 78 82
6–12 254,695 5 5
[ 12 53,461 17 13
*Exchangeable versus fixed femoral neck THAs; percentages for fixed neck cement types = 101% owing to rounding; CoC = ceramic-on-
ceramic; CoP = ceramic-on-polyethylene; MoM = metal-on-metal; MoP = metal-on-polyethylene; AH no BZD = anxiolytic or hypnotic
nonbenzodiazepines.
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implantation, medications apart from psychostimulant and
antiosteoporotic drugs, and center activity, were associated
with prosthetic survivorship after controlling for all studied
covariates; revision risk also was greater in patients who
received an implant for a traumatic indication (Table 2).
During the median 45-month followup (mean, 42
months; minimum, 1 day; maximum, 6 years), 11,968
individuals underwent prosthetic revision. The prosthetic
revision rate was 4%. The overall cumulative incidence for
revision, when taking into account death as a competing
risk, was 1.9% at 1 year, 2.7% at 2 years, 3.2% at 3 years,
3.8% at 4 years, 4.3% at 5 years, and 4.7% at 6 years
followup. The median time-to-event for all-cause revision
was 338 days (interquartile range, 56–816 days). Fifty-nine
percent of revised exchangeable neck THA implants were
replaced with fixed neck femoral stems (compared with 3%
of primary fixed necks replaced with an exchangeable stem
when revised). Among patients who had revision surgery,
we also compared stem-specific revision (defined as revi-
sion of the head only, or head and neck, or head, neck, and
stem) rate according to the type of neck; this rate was
higher in exchangeable neck THAs compared with fixed
neck THAs (39% versus 34%; p = 0.016).
Cause-Specific Revision Risk
Patients who had THAs with an exchangeable neck implant
were more likely to undergo revision for implant failure or
periprosthetic fracture, and for mechanical complications
(Table 3). Adjusted HRs for revision resulting from
implant failure or periprosthetic fracture and adjusted HRs
for revision resulting from mechanical complication were,
respectively, 1.68 (95% CI, 1.24–2.27; p\0.001) and 1.27
(95% CI, 1.13–1.43; p \ 0.001) for exchangeable neck
THAs compared with fixed ones. Similar results were
observed when stratifying for gender, age group, indica-
tion, cementation type, and bearing surface (Supplemental
Table 2. Supplemental materials are available with the
online version of CORR1.). Median time-to-event was,
respectively, 93 (interquartile range [IQR], 32–498 days),
146 (IQR, 31–759 days), 210 (IQR, 30–708 days), 440
(IQR, 126–912 days), and 436 days (IQR, 170–850 days)
for revisions resulting from dislocation, implant failure or
periprosthetic fracture, infection, mechanical complication,
and unspecified cause, respectively.
Discussion
Exchangeable neck stems have been used in THA to
improve restoration of anteversion, offset, and limb length,
and to reduce the risk of dislocation. However neck
exchangeability has been reported to result in adverse
effects such as stem fractures and acute local tissue reac-
tion. Whether they result in a net improvement to or
impairment of reconstructive survivorship remains con-
troversial, with inconsistent results in relatively few
Fig. 3 The cumulative inci-
dence of revision THA
according to the type of femoral
neck is shown.
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Table 2. Associations among THA, patients, hospital stay characteristics, and THA revision
Covariates Values Number Revision (%) HR 95% CI p Value Adjusted
HR*,
95% CI p Value
THA characteristics
Exchangeable neck No 315,177 3.7 1 Reference \0.0001 1 Reference \0.001




THA cement type Cemented 34,376 3.0 1 Reference \0.0001 1 Reference \0.001



























MoP 154,802 3.5 1 Reference 1 Reference
Patient characteristics





Female 201,930 3.6 1 Reference 1 Reference





60–74 122,590 3.8 1 Reference 1 Reference




Trauma indication No 246,940 3.7 1 Reference \0.0001 1 Reference \0.001




Parkinson disease No 310,950 3.6 1 Reference \0.0001 1 Reference \0.001




Diabetes mellitus No 283,633 3.7 1 Reference 0.24 1 Reference 0.491




Morbid Obesity No 299,430 3.6 1 Reference 0.0004 1 Reference \0.001





BZD No 160,819 3.0 1 Reference \0.0001 \0.001




AH no BZD No 278,574 3.5 1 Reference \0.0001 1 Reference \0.001




Antidepressant No 250,690 3.4 1 Reference \0.0001 1 Reference \0.001




Antipsychotic No 301,744 3.6 1 Reference \0.0001 1 Reference 0.348
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comparative studies on the topic [2, 14, 17] (Table 4). In
our study, which included a large, relatively unselected
population, we found that the risk of revision was higher for
exchangeable neck THAs compared with fixed ones. After
controlling for potential confounding variables such as
patient age, sex, comorbidities, indication for THA, THA
bearing, cementation, and the center characteristics, we
found that implantation of an exchangeable femoral neck
THA was associated with an increased hazard ratio of
revision compared with fixed neck THAs. In terms of cause-
specific revision, exchangeable neck THAs had a higher
incidence of revision for implant failure or periprosthetic
fracture and of revision for mechanical complications.
This study had several limitations. Regarding the
implants, the alloys of the components (stem, exchangeable
neck, and head) were not available, which would be
interesting since the revision rate was found to be higher
with a titanium alloy-cobalt alloy configuration [2]. In
addition, the detailed design of the implant (such as the
head diameter, surface finish, taper geometry, among oth-
ers) was not available, nor was the brand of the implant;
some models and designs of exchangeable neck implants
seem to be better than others [2]. Consequently, our results
might hide heterogeneity in the revision rates between the
different kinds of exchangeable neck implants available on
the market. Some specific exchangeable neck stem designs
may offer similar survivorship to fixed neck stem designs.
Nonetheless, we were interested in assessing a possible
class issue regarding exchangeable neck stems, whatever
the model. Our results showed exchangeable neck THAs
have poorer survivorship than fixed neck ones, consistent
with the results of the Australian registry [2], which found
the same for all six exchangeable neck implants. Making
the brand name of the THA implant available in hospital
claims in the future might be of great interest. Other lim-
itations were the lack of information regarding the surgical
approach and use of dual-mobility bearing surfaces. This
information was not available in the databases. We
acknowledge that some complications, such as dislocations
and periprosthetic fractures, are associated with the surgi-
cal technique [1, 11, 25], and dual-mobility articulations
designed to reduce the risk of dislocation appear to be
helpful [12], despite some remaining concerns about
intraprosthetic dislocation [47].
Although we did not study stem-specific revision as the
main outcome, we found in additional analysis that the
Table 2. continued
Covariates Values Number Revision (%) HR 95% CI p Value Adjusted
HR*,
95% CI p Value
Psychostimulant No 320,722 3.7 1 Reference 0.31 1 Reference 0.769




Antiosteoporotic No 281,797 3.7 1 Reference 0.02 1 Reference 0.008




Oral corticcosteroı¨ds No 240,910 3.5 1 Reference \0.0001 1 Reference \0.001










Private 187,255 3.7 1 Reference 1 Reference









[ 38 72,199 3.3 1 Reference 1 Reference





6–12 254,695 3.4 1 Reference 1 Reference




*p value class versus reference; adjusted hazard ratio of THA revision from multivariate Fine and Gray full regression model (adjusted for THA
characteristics, patient characteristics, treatments, and hospital stay characteristics); HR = hazard ratio; CoC = ceramic-on-ceramic; CoP =
ceramic-on-polyethylene; MoM = metal-on-metal; MoP = metal-on-polyethylene; BZD = benzodiazepine; AH no BZD = anxiolytic or hypnotic
nonbenzodiazepines.
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stem-specific revision rate was higher for exchangeable
neck THAs compared with fixed neck ones; the mechanism
associated with these findings need to be confirmed in other
studies. Among the hips revised for implant failure or
periprosthetic fracture, we were not able to distinguish
between periprosthetic fractures and implant failures.
Although fractures of the neck are not uncommon with
exchangeable femoral components, these events are prob-
ably mainly periprosthetic fractures, which represent one of
the top five most-frequent causes for revision [61].
Regarding the mechanical complication designation, this
covers a wide range of different types of failures and
because of the nature of the data we used, we were not able
to identify the mechanism having led to the revision. Pre-
vious studies were conducted to understand the
mechanisms of failure related to the exchangeable neck
implant. Corrosion at the exchangeable neck-body stem,
fretting, or mechanically assisted crevice corrosion was
identified as specifically associated with the femoral
exchangeable neck, possibly resulting in adverse local
tissue reactions [24, 30, 36, 39, 45, 51, 52]. Other typical
findings include iliopsoas and abductor tendinopathy,
peritendinous collections, and metallic debris, which might
generate osteolysis [13, 29]. We assume some of the
revisions resulting from mechanical complications in our
cohort probably included these typical issues, although we
were not able to identify them precisely. Finally, the
accuracy of primary THA and revision procedure codes we
used as inclusion and outcome criteria might be open to
criticism. However, in our algorithm, we checked the
agreement between the coded procedure and the implanted
device to track for coding errors and we excluded the few
patients (5.5%) with incoherent data. Moreover, this data-
base is used to calculate payments for inpatient care with
internal and external quality control processes. Coding
errors, if any, would be marginal and likely would not
differ among the study groups.
The overall risk of prosthetic revision observed after 45
months median followup is consistent with data from
international registries, and supports the external validity of
our study (Table 4). Likewise, the higher failure rate we
found for exchangeable femoral neck THAs (Table 2) is
consistent with rates in some previous studies (Table 4).
Nonetheless, in the Australian registry, the risk of revision
for exchangeable neck THAs was almost twice that of fixed
neck THAs [2], an effect size much higher than what we
observed. We speculate but cannot prove that this may be a
function of the models, types, and brands of exchangeable
neck implants used. The risk of revision varies from 3% to
18% at 5 years in the Australian registry [2], and was
reported as much as 28% for one specific model [33]. We
believe the lower (5%) revision rate we found might be the
result of two poorly performing stems being rarely used in
our population, and the exchangeable neck models with the
highest failure rates in the Australian registry were not
distributed in France. Revision risk also varies according to
stem-neck interface material [2], with a titanium-cobalt
chromium interface experiencing 1.5- to twofold higher
risks of revision than a titanium-titanium interface. In
addition to the Australian registry, two studies comparing
THA survivorship according to type of neck both focused
on only one model of exchangeable neck THA [14, 17] and
included small cohorts, with findings opposite those of the
Australian registry (Table 4). Our study therefore fills a
gap in knowledge, not only because it is a nationwide
‘‘real-life’’ cohort, with different devices implanted, but
also because we were able to control for important con-
founding factors in our analyses.
Table 3. Comparison of overall and cause-specific risks of THA revision according to type of THA femoral neck
Cause of revision Frequency of THA revision p Value Cause-specific p Value
Patients with fixed neck
(n = 315,177 [97%])
Patients with
exchangeable neck
(n = 8931 [3%])
Risk of revision associated with
type of femoral neck
Number Percent Number Percent Adjusted HR* 95% HR CI
All-cause 11,968 3.7 442 4.9 \ 0.001 1.26 1.14–1.38 \ 0.001
Periprosthetic fracture or implant failure 1050 0.3 45 0.5 \ 0.001 1.68 1.24–2.27 \ 0.001
Dislocation 2644 0.8 86 1.0 0.117 1.15 0.92–1.42 0.222
Infection 1345 0.4 37 0.4 0.992 0.95 0.69–1.33 0.954
Mechanical complication 7817 2.4 300 3.4 \ 0.001 1.27 1.13–1.43 \ 0.001
Other 285 0.1 15 0.1 0.052 1.62 0.96–2.76 0.073
Sum of different causes of revision (n = 13,141)[number of all-cause revisions (n = 11,968) because each revision could have multiple causes;
*cause-specific adjusted hazard ratio of THA revision from multivariate Cox full model (adjusted for THA characteristics, patient characteristics,
treatments, and hospital stay characteristics); HR = hazard ratio.
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Table 4. Registry and literature data for exchangeable and fixed femoral neck THA revision rates and risk
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Regarding cause-specific revision, Wright et al. [60],
Sporer et al. [53], and Talmo et al. [55] presented case
reports of exchangeable femoral neck breakage or sponta-
neous dissociation. Our results regarding cause-specific
revision risk extend this finding of higher risk of revision
because of implant failure or periprosthetic fracture and
because of mechanical complications in a large nationwide
cohort. We found no association between revision
attributable to dislocation and exchangeable neck THAs.
Neck exchangeability was not found to be efficient in
reducing the dislocation rate [50], yet restoration of offset
and reducing the risk of dislocation are the main purposes
of exchangeable femoral necks. Our work provides an
answer regarding whether an exchangeable femoral neck
results in a net improvement to or an impairment of
reconstructive survivorship.
Exchangeable-neck THAs have a poorer survivorship
independent of other prosthetic revision risk factors. If
causal, it implies patients receiving exchangeable neck
THAs are not given the best possible chances compared
with patients receiving fixed neck THAs. Whatever the
mechanism, expected anatomic and functional benefits
should be assessed carefully before choosing this design,
which might be reserved for patients with severe proximal
femoral deformities that preclude the use of fixed neck
femoral stems.
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